Primary sclerosing cholangitis: Etiopathogenesis and clinical management

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Primary sclerosing cholangitis (PSC) is a chronic inflammatory liver disease characterized by the destruction of medium to large-sized bile ducts and intense, concentric fibrosis. Complications from PSC include bacterial cholangitis, cirrhosis, and cholangiocarcinoma and a therapy that might alter the natural history of the disease remains lacking. Our understanding of the pathogenesis of PSC also remains rudimentary but several theories exist, suggesting roles for genetic susceptibility, abnormal innate immune responses lymphocyte trafficking, and toxic bile formation. Medical and surgical therapies, short of liver transplantation, have been disappointing. Currently, the management of PSC is aimed largely at the endoscopic treatment of dominant biliary strictures and complications of cholestasis until the disease has progressed to cirrhosis, at which time liver transplantation is indicated. Progress in our basic understanding of PSC is desperately needed in order to rationally design new therapeutic approaches to this disease.

Original languageEnglish (US)
Pages (from-to)1683-1705
Number of pages23
JournalFrontiers in Bioscience - Elite
Volume4 E
Issue number5
StatePublished - Jan 1 2012

Fingerprint

Sclerosing Cholangitis
Liver
Fibrosis
Liver Transplantation
Lymphocytes
Poisons
Cholangitis
Cholangiocarcinoma
Ducts
Cholestasis
Therapeutics
Genetic Predisposition to Disease
Bile Ducts
Innate Immunity
Bile
Liver Diseases
Pathologic Constriction

Keywords

  • Genetics
  • Immunology
  • Inflammatory Bowel Disease
  • Primary Sclerosing Cholangitis
  • Review
  • Treatment

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Primary sclerosing cholangitis : Etiopathogenesis and clinical management. / Gupta, Asha; Bowlus, Christopher.

In: Frontiers in Bioscience - Elite, Vol. 4 E, No. 5, 01.01.2012, p. 1683-1705.

Research output: Contribution to journalArticle

@article{c87f4a0cb4f54d6cae415b1df1834e35,
title = "Primary sclerosing cholangitis: Etiopathogenesis and clinical management",
abstract = "Primary sclerosing cholangitis (PSC) is a chronic inflammatory liver disease characterized by the destruction of medium to large-sized bile ducts and intense, concentric fibrosis. Complications from PSC include bacterial cholangitis, cirrhosis, and cholangiocarcinoma and a therapy that might alter the natural history of the disease remains lacking. Our understanding of the pathogenesis of PSC also remains rudimentary but several theories exist, suggesting roles for genetic susceptibility, abnormal innate immune responses lymphocyte trafficking, and toxic bile formation. Medical and surgical therapies, short of liver transplantation, have been disappointing. Currently, the management of PSC is aimed largely at the endoscopic treatment of dominant biliary strictures and complications of cholestasis until the disease has progressed to cirrhosis, at which time liver transplantation is indicated. Progress in our basic understanding of PSC is desperately needed in order to rationally design new therapeutic approaches to this disease.",
keywords = "Genetics, Immunology, Inflammatory Bowel Disease, Primary Sclerosing Cholangitis, Review, Treatment",
author = "Asha Gupta and Christopher Bowlus",
year = "2012",
month = "1",
day = "1",
language = "English (US)",
volume = "4 E",
pages = "1683--1705",
journal = "Frontiers in Bioscience - Elite",
issn = "1945-0494",
publisher = "Frontiers in Bioscience",
number = "5",

}

TY - JOUR

T1 - Primary sclerosing cholangitis

T2 - Etiopathogenesis and clinical management

AU - Gupta, Asha

AU - Bowlus, Christopher

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Primary sclerosing cholangitis (PSC) is a chronic inflammatory liver disease characterized by the destruction of medium to large-sized bile ducts and intense, concentric fibrosis. Complications from PSC include bacterial cholangitis, cirrhosis, and cholangiocarcinoma and a therapy that might alter the natural history of the disease remains lacking. Our understanding of the pathogenesis of PSC also remains rudimentary but several theories exist, suggesting roles for genetic susceptibility, abnormal innate immune responses lymphocyte trafficking, and toxic bile formation. Medical and surgical therapies, short of liver transplantation, have been disappointing. Currently, the management of PSC is aimed largely at the endoscopic treatment of dominant biliary strictures and complications of cholestasis until the disease has progressed to cirrhosis, at which time liver transplantation is indicated. Progress in our basic understanding of PSC is desperately needed in order to rationally design new therapeutic approaches to this disease.

AB - Primary sclerosing cholangitis (PSC) is a chronic inflammatory liver disease characterized by the destruction of medium to large-sized bile ducts and intense, concentric fibrosis. Complications from PSC include bacterial cholangitis, cirrhosis, and cholangiocarcinoma and a therapy that might alter the natural history of the disease remains lacking. Our understanding of the pathogenesis of PSC also remains rudimentary but several theories exist, suggesting roles for genetic susceptibility, abnormal innate immune responses lymphocyte trafficking, and toxic bile formation. Medical and surgical therapies, short of liver transplantation, have been disappointing. Currently, the management of PSC is aimed largely at the endoscopic treatment of dominant biliary strictures and complications of cholestasis until the disease has progressed to cirrhosis, at which time liver transplantation is indicated. Progress in our basic understanding of PSC is desperately needed in order to rationally design new therapeutic approaches to this disease.

KW - Genetics

KW - Immunology

KW - Inflammatory Bowel Disease

KW - Primary Sclerosing Cholangitis

KW - Review

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84860856008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860856008&partnerID=8YFLogxK

M3 - Article

C2 - 22201985

AN - SCOPUS:84860856008

VL - 4 E

SP - 1683

EP - 1705

JO - Frontiers in Bioscience - Elite

JF - Frontiers in Bioscience - Elite

SN - 1945-0494

IS - 5

ER -